CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel

Pharmacogenomics

Volumn 12, Issue 2, 2011, Pages 141-144

  Peters, Bas J M ^a   Harmsze, Ankie M ^a,b   Ten Berg, Jurriën M ^a   Maitland Van Der Zee, Anke Hilse ^b   Tjoeng, Mathieu M ^a   De Boer, Anthonius ^b   Deneer, Vera H M ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

ABCB1; cardiovascular disease; clopidogrel; CYP2C19; pharmacogenetics; prasugrel

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; IRBESARTAN; MULTIDRUG RESISTANCE PROTEIN 1; PRASUGREL;

ALLELE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; ENZYME ACTIVITY; GENE FUNCTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LOSS OF FUNCTION MUTATION; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION INHIBITION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ARYL HYDROCARBON HYDROXYLASES; GENETIC VARIATION; HUMANS; INDIVIDUALIZED MEDICINE; P-GLYCOPROTEIN; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 79951885679     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.211     Document Type: Editorial

References (20)

1. Grotemeyer KH, Scharafinski HW, Husstedt IW: Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb. Res. 71(5), 397-403 (1993).
2. Breet NJ, van Werkum JW, Bouman HJ et al.: Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303(8), 754-762 (2010).
3. Mega JL, Close SL, Wiviott SD et al.: Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009).
4. Mega JL, Simon T, Collet J-P et al.: Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16), 1821-1830 (2010).
5. Wallentin L, James S, Storey RF et al.: Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376(9749), 1320-1328 (2010).
6. Paré G, Mehta SR, Yusuf S et al.: Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 363, 1704-1714 (2010).
7. Harmsze AM, van Werkum JW, Ten Berg JM et al.: CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur. Heart J. 31(24), 3046-3053 (2010).
8. Sibbing D, Gebhard D, Koch W et al.: Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J. Thromb. Haemost. 8(8), 1685-1693 (2010).
9. Tiroch KA, Sibbing D, Koch W, Roosen-Runge T et al.: Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am. Heart J. 160(3), 506-512 (2010).
10. Kimchi-Sarfaty C, Oh JM, Kim IW et al.: A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811), 525-528 (2007).
11. Taubert D, von Beckerath N, Grimberg G et al.: Impact of P-glycoprotein on clopidogrel absorption. Clin. Pharmacol. Ther. 80(5), 486-501 (2006).
12. Mega JL, Close SL, Wiviott SD et al.: Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 376(9749), 1312-1319 (2010).
13. Simon T, Verstuyft C, Mary-Krause M et al.: Genetic determinants of response to clopidogrel and cardiovascular events. N Engl. J. Med. 360(4), 363-375 (2009).
14. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM: ACCF/AHA Clopidogrel clinical alert: approaches to the FDA 'boxed warning': a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 122(5), 537-557 (2010).
15. Gladding P, Webster M, Zeng I et al.: The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc. Interv. 1(6), 620-627 (2008).
16. Marcucci R, Gori AM, Paniccia R et al.: Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119(2), 237-242 (2009).
17. Price MJ, Endemann S, Gollapudi RR et al.: Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur. Heart J. 29(8), 992-1000 (2008).
18. Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment (GIANT) www.clinicaltrials.gov/ct2/results?term=NCT01134380
19. Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study (GeCCO) www.clinicaltrials.gov/ct2/results?term=NCT00995514
20. Thrombocyte Activity Reassessment and GEnoTyping for PCI(TARGET-PCI) www.clinicaltrials.gov/ct2/results?term=NCT01177592